HUP0301269A3 - Phthalazinone derivatives and pharmaceutical compositions containing them - Google Patents

Phthalazinone derivatives and pharmaceutical compositions containing them

Info

Publication number
HUP0301269A3
HUP0301269A3 HU0301269A HUP0301269A HUP0301269A3 HU P0301269 A3 HUP0301269 A3 HU P0301269A3 HU 0301269 A HU0301269 A HU 0301269A HU P0301269 A HUP0301269 A HU P0301269A HU P0301269 A3 HUP0301269 A3 HU P0301269A3
Authority
HU
Hungary
Prior art keywords
pharmaceutical compositions
compositions containing
phthalazinone derivatives
phthalazinone
derivatives
Prior art date
Application number
HU0301269A
Other languages
English (en)
Original Assignee
Maybridge Plc Tintagel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0026505.8A external-priority patent/GB0026505D0/en
Application filed by Maybridge Plc Tintagel filed Critical Maybridge Plc Tintagel
Publication of HUP0301269A2 publication Critical patent/HUP0301269A2/hu
Publication of HUP0301269A3 publication Critical patent/HUP0301269A3/hu
Publication of HU228960B1 publication Critical patent/HU228960B1/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30Phthalazines
    • C07D237/32Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
HU0301269A 2000-10-30 2001-10-25 Ftalazinon-származékok HU228960B1 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0026505.8A GB0026505D0 (en) 2000-10-30 2000-10-30 Phthalazinone derivatives
US27506601P 2001-03-12 2001-03-12
PCT/GB2001/004729 WO2002036576A1 (en) 2000-10-30 2001-10-25 Phthalazinone derivatives

Publications (3)

Publication Number Publication Date
HUP0301269A2 HUP0301269A2 (hu) 2003-12-29
HUP0301269A3 true HUP0301269A3 (en) 2004-03-29
HU228960B1 HU228960B1 (hu) 2013-07-29

Family

ID=26245211

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301269A HU228960B1 (hu) 2000-10-30 2001-10-25 Ftalazinon-származékok

Country Status (18)

Country Link
EP (1) EP1330442B1 (hu)
JP (1) JP2009149643A (hu)
KR (1) KR100804564B1 (hu)
CN (1) CN100400518C (hu)
AU (2) AU2001295789B2 (hu)
BR (1) BR0115062A (hu)
CA (1) CA2423279C (hu)
CY (1) CY1111380T1 (hu)
EA (1) EA006300B1 (hu)
GB (1) GB2384776C (hu)
HK (1) HK1056880A1 (hu)
HU (1) HU228960B1 (hu)
IL (2) IL155645A0 (hu)
MX (1) MXPA03003218A (hu)
NO (1) NO325637B1 (hu)
NZ (1) NZ525138A (hu)
PL (1) PL223343B1 (hu)
WO (1) WO2002036576A1 (hu)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
AU2003229953A1 (en) * 2002-04-30 2003-11-17 Kudos Pharmaceuticals Limited Phthalazinone derivatives
BRPI0408284B8 (pt) * 2003-03-12 2021-05-25 Kudos Pharm Ltd compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
TW200505441A (en) * 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
EP1620108B1 (en) 2003-05-01 2012-06-06 Bristol-Myers Squibb Company Pyrazole-amine compounds useful as kinase inhibitors
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
DK1684736T3 (da) * 2003-12-01 2011-11-21 Kudos Pharm Ltd Inhibitorer af DNA-skadereparation til behandling af cancer
CN1905864B (zh) * 2003-12-01 2011-04-06 库多斯药物有限公司 用于治疗癌症的dna损伤修复抑制剂
MXPA06014542A (es) * 2004-06-30 2007-03-23 Janssen Pharmaceutica Nv Derivados de ftalazina como inhibidores de poli(adp-ribosa) polimerasa-i.
GB0419072D0 (en) * 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
KR20070057859A (ko) * 2004-08-26 2007-06-07 쿠도스 파마슈티칼스 리미티드 4-헤테로아릴메틸 치환된 프탈라지논 유도체
GB0428111D0 (en) * 2004-12-22 2005-01-26 Kudos Pharm Ltd Pthalazinone derivatives
GB0521373D0 (en) * 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
GB0610680D0 (en) 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
CA2652167A1 (en) 2006-05-31 2007-12-06 Philip Jones Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase (parp)
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
US20080280910A1 (en) * 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
GB0716532D0 (en) 2007-08-24 2007-10-03 Angeletti P Ist Richerche Bio Therapeutic compounds
AU2008299721A1 (en) 2007-09-14 2009-03-19 Astrazeneca Ab Phthalazinone derivatives
CN101821242B (zh) * 2007-10-17 2013-07-24 库多斯药物有限公司 4-[3-(4-环丙烷羰基-哌嗪-1-羰基)-4-氟-苄基]-2h-酞嗪-1-酮
JP5758630B2 (ja) 2007-11-15 2015-08-05 エンメエッセディ・イタリア・エッセ・エッレ・エッレ Parp阻害剤としてのピリダジノン誘導体
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
LT2346495T (lt) 2008-10-07 2016-10-10 Astrazeneca Uk Limited Farmacinė kompozicija 514
KR101033492B1 (ko) * 2009-01-22 2011-05-12 김기산 현수막 게시대
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
US8871765B2 (en) 2010-07-27 2014-10-28 Cadila Healthcare Limited Substituted 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one derivatives as poly (ADP-ribose) polymerase-1 inhibitors
CN102372716A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CN102485721B (zh) * 2010-12-03 2015-12-09 曹亚 取代的2,3-二氮杂萘酮化合物及其用途
EP3925962A1 (en) 2011-05-31 2021-12-22 Rakovina Therapeutics Inc. Tricyclic inhibitors of poly(adp-ribose) polymerase
CN102344425B (zh) * 2011-07-26 2014-04-09 兰州大学 一种合成含三氟甲基呋喃化合物的方法
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
CN102633732B (zh) * 2012-03-08 2014-07-30 江苏先声药物研究有限公司 一类酞嗪酮衍生物及其应用
KR20150002713A (ko) * 2012-03-28 2015-01-07 뉴로포레 테라피스, 인코포레이티드 단백질 응집 저해제로서의 페닐-우레아 및 페닐-카바메이트 유도체
HUE030613T2 (hu) 2012-12-31 2017-05-29 Cadila Healthcare Ltd Helyettesített ftálazin-1(2H)-on-származékok mint poli-(ADP-ribóz)-polimeráz-1 szelektív inhibitorai
EP3252049A1 (en) 2013-01-18 2017-12-06 Bristol-Myers Squibb Company Phthalazinones and isoquinolinones as rock inhibitors
MX365950B (es) 2013-03-13 2019-06-19 Flatley Discovery Lab Llc Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
EP3013804B1 (en) * 2013-06-24 2017-02-01 Merck Patent GmbH Phthalazine derivatives
KR101670126B1 (ko) 2013-09-13 2016-10-27 일동제약(주) 신규 프탈라지논 유도체 및 그 제조방법
GB201317609D0 (en) 2013-10-04 2013-11-20 Cancer Rec Tech Ltd Inhibitor compounds
US9902702B2 (en) 2014-07-15 2018-02-27 Bristol-Myers Squibb Company Spirocycloheptanes as inhibitors of rock
US10202361B2 (en) 2014-08-29 2019-02-12 Fmc Corporation Pyridazinones as herbicides
GB201505658D0 (en) 2015-04-01 2015-05-13 Cancer Rec Tech Ltd Inhibitor compounds
CN106146492A (zh) 2015-04-17 2016-11-23 上海汇伦生命科技有限公司 杂环并咪唑类化合物、其药物组合物及其制备方法和用途
US10562886B2 (en) 2015-05-21 2020-02-18 The Regents Of The University Of California Anti-cancer compounds
WO2017013593A1 (en) 2015-07-22 2017-01-26 Lupin Limited Isoquinolinone derivatives as parp inhibitors
KR101896567B1 (ko) 2015-07-23 2018-09-07 인스티튜트 큐리 암 치료를 위한 디베이트 분자와 parp 억제제의 병용 용도
JP2018523679A (ja) 2015-08-17 2018-08-23 ルピン・リミテッド Parp阻害剤としてのヘテロアリール誘導体
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
PT3475272T (pt) 2016-06-24 2023-12-15 Univ California Derivados de ftalazina como inibidores de parp1, parp2 e/ou tubulina úteis para o tratamento do cancro
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
CN107955001A (zh) 2016-10-14 2018-04-24 上海汇伦生命科技有限公司 抗肿瘤杂环并咪唑类化合物的药用盐
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
CN108358850B (zh) * 2018-02-11 2021-01-26 中国药科大学 PARP-1和Tankyrase1/2多靶点抑制剂、其制法及用途
US20200407720A1 (en) 2018-03-13 2020-12-31 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
GB201913030D0 (en) 2019-09-10 2019-10-23 Francis Crick Institute Ltd Treatment of hr deficient cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
BR112022021321A2 (pt) 2020-04-21 2022-12-20 Idience Co Ltd Formas cristalinas do composto de ftalazinona.
EP4139298A4 (en) 2020-04-21 2024-05-22 Idience Co., Ltd. PROCESS FOR PREPARING A PHTHALAZINONE DERIVATIVE AND ITS INTERMEDIATES
JP2023524212A (ja) 2020-04-28 2023-06-09 ライゼン ファーマシューティカルズ アーゲー ポリ(adp-リボース)ポリメラーゼ(parp)阻害剤として有用な新規化合物
WO2021224381A1 (en) 2020-05-07 2021-11-11 Astrazeneca Ab Combination therapy for treating cancer
CN114276301A (zh) * 2020-09-27 2022-04-05 江西青峰药业有限公司 Parp抑制剂的中间体化合物及其制备方法和应用
US12059419B2 (en) 2020-10-16 2024-08-13 Idience Co., Ltd. Pharmaceutical composition comprising phthalazinone derivatives
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
WO2022170952A1 (zh) * 2021-02-09 2022-08-18 苏州阿尔脉生物科技有限公司 一种作为sos1抑制剂的多环哒嗪酮类衍生物、其制备方法及用途
CA3214298A1 (en) 2021-04-08 2022-10-13 Swaroop Kumar Venkata Satya VAKKALANKA Inhibitors of poly(adp-ribose) polymerase

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274185A (en) * 1963-10-08 1966-09-20 S E Massengill Company Phthalazine derivatives
GB8610018D0 (en) * 1986-04-24 1986-05-29 Fujisawa Pharmaceutical Co Phthalazine derivatives
ES2067508T3 (es) * 1988-08-19 1995-04-01 Warner Lambert Co Dihidroisoquinolinonas sustituidas y compuestos relacionados como potenciadores de los efectos letales de la radiacion y de ciertos agentes quimioterapeuticos; compuestos seleccionados, analogos y proceso.
DE19630250C1 (de) * 1996-07-26 1997-08-28 Krupp Vdm Gmbh Vollmetallischer Oxidationskatalysator
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US5888529A (en) * 1997-03-28 1999-03-30 The Regents Of The University Of California Ileus treatment method
US6677333B1 (en) * 1999-01-26 2004-01-13 Ono Pharmaceutical Co., Ltd. 2H-phthalazin-1-one derivatives and drug containing its derivatives as active ingredient
GB0026505D0 (en) * 2000-10-30 2000-12-13 Kudos Pharm Ltd Phthalazinone derivatives

Also Published As

Publication number Publication date
HK1056880A1 (en) 2004-03-05
KR100804564B1 (ko) 2008-02-20
EA200300531A1 (ru) 2003-10-30
EP1330442A1 (en) 2003-07-30
CA2423279A1 (en) 2002-05-10
AU2001295789C1 (en) 2002-05-15
HU228960B1 (hu) 2013-07-29
GB2384776A (en) 2003-08-06
CY1111380T1 (el) 2015-08-05
GB0309190D0 (en) 2003-05-28
IL155645A (en) 2008-04-13
CN100400518C (zh) 2008-07-09
WO2002036576A1 (en) 2002-05-10
JP2009149643A (ja) 2009-07-09
CA2423279C (en) 2011-07-05
NZ525138A (en) 2004-03-26
NO325637B1 (no) 2008-06-30
NO20031498D0 (no) 2003-04-02
IL155645A0 (en) 2003-11-23
CN1473154A (zh) 2004-02-04
KR20030059811A (ko) 2003-07-10
GB2384776B (en) 2004-03-03
AU2001295789B2 (en) 2006-05-11
NO20031498L (no) 2003-04-02
AU9578901A (en) 2002-05-15
BR0115062A (pt) 2004-02-17
MXPA03003218A (es) 2004-12-03
HUP0301269A2 (hu) 2003-12-29
PL223343B1 (pl) 2016-10-31
EA006300B1 (ru) 2005-10-27
EP1330442B1 (en) 2011-01-19
PL360909A1 (en) 2004-09-20
GB2384776C (en) 2006-02-03

Similar Documents

Publication Publication Date Title
HUP0301269A3 (en) Phthalazinone derivatives and pharmaceutical compositions containing them
IL152451A0 (en) 2-chloro-2-nitrophenylcarboxamide derivatives and pharmaceutical compositions containing the same
HUP0301178A3 (en) Glucopyranosyloxybenzylbenzene derivatives and pharmaceutical compositions containing the same
IL153123A0 (en) N-ureidoheterocycloalkyl-piperidine derivatives and pharmaceutical compositions containing the same
IL156407A0 (en) Pyrazole derivatives and pharmaceutical compositions containing the same
IL154786A0 (en) Pyrazole derivatives and pharmaceutical compositions containing the same
IL145757A0 (en) Pyrazole derivatives and pharmaceutical compositions containing the same
IL145756A0 (en) Pyrazole derivatives and pharmaceutical compositions containing the same
IL151372A0 (en) Cyclopropyl-fused pyrrolidine derivatives and pharmaceutical compositions containing the same
HUP0400837A3 (en) 2-phenyl-thiazole derivatives, their use and pharmaceutical compositions containing them
HUP0204474A3 (en) 1h-imidazopyridine derivatives, pharmaceutical compositions containing them and their use
IL161616A0 (en) Indazolypyrrolotriazine derivatives and pharmaceutical compositions containing the same
IL158044A0 (en) Cyclopropylindole derivatives and pharmaceutical compositions containing the same
IL158300A0 (en) Bisarylimidazol derivatives and pharmaceutical compositions containing the same
IL150449A0 (en) Aniline derivatives and pharmaceutical compositions containing the same
IL156812A0 (en) Phthalazinone-piperidino derivatives and pharmaceutical compositions containing the same
IL157908A0 (en) Phthalazinone derivatives and pharmaceutical compositions containing the same
IL152846A0 (en) Pyridazinone derivatives and pharmaceutical compositions containing the same
IL147214A0 (en) 1-methylcarbapenem derivatives and pharmaceutical compositions containing the same
HUP0303184A3 (en) Substituted c-cyclohexylmethylamine derivatives and pharmaceutical compositions containing them
HUP0200468A3 (en) Resorcinol derivatives and pharmaceutical compositions containing them
HUP0303204A3 (en) 1-methylcarbapenem derivatives and pharmaceutical compositions containing them
HUP0200088A3 (en) Pyridazin-3-one derivatives and pharmaceutical compositions containing the same
IL156372A0 (en) Carbazole derivatives and pharmaceutical compositions containing the same
AU4834101A (en) N-deacetylthiocolchicine derivatives and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: KUDOS PHARMACEUTICALS LIMITED, GB

Free format text: FORMER OWNER(S): KUDOS PHARMACEUTICALS LIMITED, GB; MAYBRIDGE PLC, GB

HC9A Change of name, address

Owner name: KUDOS PHARMACEUTICALS LIMITED, GB

Free format text: FORMER OWNER(S): KUDOS PHARMACEUTICALS LIMITED, GB; MAYBRIDGE PLC, GB; KUDOS PHARMACEUTICALS LIMITED, GB